FibroBiologics, Inc., a biotechnology company focused on developing therapies for chronic diseases using fibroblasts, announced that Dr. Chuo Fang presented research at the Society for Investigative ...
ALBUQUERQUE, N.M., May 19, 2020 (GLOBE NEWSWIRE) -- The world is especially stressful these days, which is understandable—and perhaps unavoidable. Unfortunately, stress takes a toll on a person’s ...
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform
FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...
HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
We believe it will take a positive biologic process created through fibroblast or a stem cell through immunotherapy or gene therapy. The three ways we think you'll be able to cure chronic diseases ...
Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In November 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced that it has received both public and private Human Research Ethics Committee ...
The palms of our hands and the bottoms of our feet aren’t the flashiest body parts, but they have a secret superpower that we don’t often appreciate—the ability to bear weight. “There was this one ...
In November 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced that it has received both public and private Human Research Ethics Committee (HREC) approvals in Australia for the planned Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results